Trials / Completed
CompletedNCT00316459
Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
A Randomized, Double-Blind, Placebo and Moxifloxacin (Open-Label) Controlled, 4-Period, Crossover Study of the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To assess the effect of ERB-041 after multiple oral doses on cardiac repolarization as assessed by the QTc interval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ERB-041 |
Timeline
- Start date
- 2006-05-01
- First posted
- 2006-04-20
- Last updated
- 2007-04-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00316459. Inclusion in this directory is not an endorsement.